Media enquiries about Barts Cancer Institute are handled through Queen Mary University of London’s press office. Find contact details and guidance here.
Barts Cancer Institute (BCI) is part of Queen Mary University of London, which has a dedicated press office and experienced communications team who handle media enquiries across the university and can be contacted inside and outside of hours.
Barts Cancer Institute also has its own communications lead, who can advise on institute-specific stories, research updates, expert commenters, and queries relating to the institute website and social media channels.
Email: press@qmul.ac.uk
Phone: +44 (0)20 7882 3600
Out of hours (5 p.m.–9 a.m.): +44 (0)7970 096 188
For more information visit the Queen Mary press information pages
Dr Charlotte Ridler
BCI Scientific Writer and Communications Manager
Email: charlotte.ridler@qmul.ac.uk
The Barts Cancer Institute is home to a broad range of cancer experts, spanning laboratory research, data science and clinical studies. Click the links below to view experts in particular cancer types or topics. If you would like help identifying or contacting an appropriate expert, please get in touch with the Queen Mary or Barts Cancer Institute media contacts.
Researchers have uncovered a mechanism that makes some cancer cells especially vulnerable to experimental drugs known as ATR inhibitors. The findings could support the development of tests to identify the patients most likely to benefit.
Publications 17 August 2026
Scientists have carried out one of the largest and most comprehensive studies to date of the genetic and clinical factors associated with cancer in British Bangladeshi and Pakistani people. The findings could help inform future efforts to make cancer screening and risk assessment more equitable.
Publications 7 August 2026
Scientists at Barts Cancer Institute, Queen Mary University of London, have uncovered an important way that cells keep their genes under control. The discovery could help explain one of the earliest molecular changes that occurs during the development of lung cancer. The study, published in Science Advances, reveals that a protein called LIMD1, which is frequently lost in lung cancer, plays a much bigger role in controlling gene activity than scientists previously realised. The findings uncover a previously hidden layer of gene regulation and may provide new insight into how normal cells begin to lose control during the earliest stages of cancer.
Publications 23 July 2026